关于委托博济医药技术开发中药1.1类新药 "复方侧柏酊"（脱发适应症）的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： ■ 登录新浪财经APP 搜索【信披】查看更多考评等级 上海小方制药股份有限公司 ● 事项概述：上海小方制药股份有限公司（以下简称"公司"）近日与博济医药科技股份有限公司（以下 简称"博济医药"）签署了《技术委托（开发）合同》，博济医药将协助公司完成中药1.1类复方侧柏酊 新药临床研究及注册，推动其完成临床试验及上市。 ● 本次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组， 亦不构成关联交易。 ● 本次交易对公司本年度经营成果无重大影响。 前期，公司与上海市皮肤病医院签署了《复方侧柏酊合作开发协议》，双方拟共同开展复方侧柏酊的新 药转化开发，具体内容详见公司于2025年6月13日披露的《关于自愿披露与上海皮肤病医院合作开发治 疗脱发中药1.1类新药复方侧柏酊的公告》（公告编号：2025-027）。为了完成复方侧柏酊的新药开 发，公司近日与博济医药签署了《技术委托（开发）合同》，博济医药将协助公司完成中药1.1类 ...

北京商报讯（记者 丁宁）9月25日晚间，小方制药（603207）发布公告称，公司近日与博济医药科技股 份有限公司（以下简称"博济医药"）签署了《技术委托（开发）合同》，博济医药将协助公司完成中药 1.1类复方侧柏酊新药临床研究及注册，推动其完成临床试验及上市。 小方制药表示，博济医药作为行业领先企业，在研发实力、技术积累和临床资源方面具有显著优势，双 方合作将充分发挥各自专长，形成协同效应，有效提升合同产品的研发效率与成功率，为产品后续申报 及上市奠定坚实基础。 ...

格隆汇9月25日丨小方制药(603207.SH)公布，公司近日与博济医药科技股份有限公司(以下简称"博济医 药")签署了《技术委托(开发)合同》，博济医药将协助公司完成中药1.1类复方侧柏酊新药临床研究及注 册，推动其完成临床试验及上市。 ...

小方制药（603207）(603207.SH)发布公告，公司近日与博济医药（300404）科技股份有限公司(简称"博 济医药")签署了《技术委托(开发)合同》，博济医药将协助公司完成中药1.1类复方侧柏酊新药临床研究 及注册，推动其完成临床试验及上市。 本次公司与博济医药签署的《技术委托(开发)合同》，是双方基于共同发展战略的一次强强联合，标志 着公司在创新药领域布局迈出重要一步。博济医药作为行业领先企业，在研发实力、技术积累和临床资 源方面具有显著优势，双方合作将充分发挥各自专长，形成协同效应，有效提升合同产品的研发效率与 成功率，为产品后续申报及上市奠定坚实基础。 ...

每经AI快讯，9月25日，小方制药（603207）(603207.SH)公告称，公司与博济医药（300404）签署《技 术委托(开发)合同》，博济医药将协助公司完成中药1.1类复方侧柏酊新药临床研究及注册，推动其完成 临床试验及上市。此次交易不构成重大资产重组，亦不构成关联交易，对公司本年度经营成果无重大影 响。 ...

智通财经APP讯，小方制药(603207.SH)发布公告，公司近日与博济医药科技股份有限公司(简称"博济医 药")签署了《技术委托(开发)合同》，博济医药将协助公司完成中药 1.1 类复方侧柏酊新药临床研究及 注册，推动其完成临床试验及上市。 本次公司与博济医药签署的《技术委托(开发)合同》，是双方基于共同发展战略的一次强强联合，标志 着公司在创新药领域布局迈出重要一步。博济医药作为行业领先企业，在研发实力、技术积累和临床资 源方面具有显著优势，双方合作将充分发挥各自专长，形成协同效应，有效提升合同产品的研发效率与 成功率，为产品后续申报及上市奠定坚实基础。 ...

Group 1: Research Basic Information - The research object is Xiaofang Pharmaceutical, belonging to the chemical pharmaceutical industry, and the reception time was September 12, 2025. The company's reception staff included the chairman and general manager Fang Zhiguang, the board secretary and financial director Luo Xiaoxu, and the independent director Yu Wei [17] Group 2: Detailed Research Institutions - The reception object was the 2025 semi - annual performance briefing of Shanghai Stock Exchange Roadshow Center Company [20] Group 3: Main Content Innovation and R & D - Xiaofang Pharmaceutical is not limited to traditional external medicine business and has started to layout the innovative drug field, with multiple innovative drug projects in different R & D stages. The company is advancing the R & D of traditional Chinese medicine class - one new drugs, including compound Cacumen Platycladi tincture for treating various types of hair loss and compound Herba Speranskiae Tuberculatae solution for antifungal use [24][27] - The compound Herba Speranskiae Tuberculatae solution was jointly developed with Shanghai University of Traditional Chinese Medicine Affiliated Yueyang Hospital of Integrated Traditional Chinese and Western Medicine before the company's listing, and details can be found in the company's IPO prospectus [29] - The qualification for innovative drug application needs to be scientifically determined based on sufficient pharmaceutical, non - clinical, and clinical research data, and the process is rigorous and complex. The company will disclose major progress in accordance with regulations [30] Overseas Business - The company has obtained the approval number for exporting drugs to Macau, China and has realized sales there. It will gradually explore other overseas markets while being aware of challenges such as differences in national regulations, complex registration processes, localization requirements, and strict quality supervision [27] Product Sales - The company is cautious about new product sales. Once there is a clear sales plan, it will announce it in a timely manner [28] Hospital Cooperation - The company focuses on the development and cooperation of various sales channels. Its products are suitable for sales in medical institutions at all levels. It also actively promotes the industry - university - research cooperation and development of innovative drugs [29]

Group 1 - Xiaofang Pharmaceutical announced a collaboration with Shanghai Skin Disease Hospital to develop a new traditional Chinese medicine for hair loss, Compound Cèbǎi Tincture, which is expected to be the first TCM formulation for hair loss in China [1] - Guizhou Sanli plans to invest 150 million RMB in a patent transfer and technical cooperation contract with Guangdong Pharmaceutical University for the development of a new TCM drug [1] - The technical cooperation will involve a total development cost of 100 million RMB for the research and development of SL&GDPU-001, a new TCM drug [2] Group 2 - Jichuan Pharmaceutical's actual controller, Cao Longxiang, transferred part of his equity in Jichuan Holdings to his son, Cao Fei, which is an internal family equity adjustment and will not affect the company's independence [2] - Junshi Biosciences received acceptance for the clinical trial application of JT118 injection, a vaccine aimed at preventing monkeypox virus infection, marking a significant step as no such vaccine has been approved in China [3] - Palin Bio announced that its controlling shareholder, Shengbang Yinghao, intends to transfer 21.03% of its shares to China National Pharmaceutical Group, which will result in a change of control [3] Group 3 - East China Pharmaceutical's subsidiary received FDA approval for the clinical trial of HDM1010 tablets, aimed at treating type 2 diabetes, enhancing the company's competitiveness in the endocrine field [4]

Industry News - The Ministry of Commerce has approved a certain number of compliant applications for rare earth-related export licenses, considering the reasonable needs and concerns of various countries in the private sector [6] - Ant International plans to apply for a stablecoin license in Hong Kong following the passage of the Stablecoin Bill, with the application to be submitted as soon as the relevant channels are opened [8] - The People's Bank of China and the State Administration of Foreign Exchange have issued measures to support the integration and development of cross-strait relations, proposing 12 policy measures to enhance financial support [8] - The Hong Kong Securities and Futures Commission is studying adjustments to the number of shares per transaction to improve the convenience of trading high-priced and fractional shares, thereby enhancing market liquidity [8] - The Guangxi Zhuang Autonomous Region has launched a special action plan to boost consumption, focusing on subsidies for the replacement of old vehicles and home appliances [8] - Urumqi plans to invest 44.815 billion yuan in 82 cultural tourism projects by 2025, with a focus on attracting high-end hotel clusters and creating comprehensive cultural tourism spaces [8] Company News - Xinhua Insurance plans to invest no more than 15 billion yuan to subscribe for private equity fund shares [11] - Vanke A announced the sale of 72.96 million A-shares from June 10 to June 12 to supplement the company's liquidity [12] - ST Gongzhi's stock will be delisted as per the Shenzhen Stock Exchange's decision [13] - ST Jinyi announced the removal of other risk warnings, with trading resuming on June 16 [14] - China Power Construction announced it won a 10.77 billion yuan EPC contract for an offshore wind power project [15] - Taiji Co., Ltd. announced that its controlling shareholder is planning a change in company control, leading to a stock suspension [17]

Core Viewpoint - The company Xiaofang Pharmaceutical (603207) is officially entering the field of traditional Chinese medicine compound preparation new drug development by collaborating with Shanghai Dermatology Hospital to develop a new product for hair loss treatment [2][3]. Group 1: Collaboration and Product Development - Xiaofang Pharmaceutical has signed a cooperation agreement with Shanghai Dermatology Hospital to jointly develop a new drug, Compound Cèbǎi Tincture, aimed at treating various types of hair loss [2]. - The collaboration aims to obtain the new drug (Class 1.1) market approval from the National Medical Products Administration, involving preclinical research and clinical trials [2][3]. - The company will pay a total of 20 million yuan for technology transfer and support, with additional sales commissions after the product is launched [2]. Group 2: Market Potential and Strategic Focus - According to the National Health Commission, the number of people suffering from hair loss in China has exceeded 250 million, with a noticeable increase in younger demographics aged 20-40 due to economic and lifestyle pressures [2]. - The Compound Cèbǎi Tincture has been well-received by patients and shows promising development prospects, potentially becoming the first traditional Chinese medicine preparation for hair loss in China [3]. - Xiaofang Pharmaceutical has a strong focus on over-the-counter external medications and aims to expand its product pipeline while optimizing research and development structures to meet family health needs [3].